Search
Crenezumab
Mechanism of action:
- blocks formation of amyloid-beta oligomers amyloid plaques [3]
Clinical trials:
- to be used in a 5 year clinical trial on ~300 family members that carry an autosomal dominant allele of presenilin-1
- Crenezumab did not reduce clinical decline in a phase 3 clinical trial of participants with early Alzheimer's disease [4]
Notes:
- Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune SA, which licensed the drug in 2006 to Genentech [2]
Interactions
drug adverse effects of anti-Alzheimer monoclonal antibody
Related
investigational therapies for treatment of Alzheimer's disease
General
anti-Alzheimer monoclonal antibody
References
- Belluck P
New Drug Trial Seeks to Stop Alzheimer's Before It Starts
New York Times< May 15, 2012
http://www.nytimes.com/2012/05/16/health/research/prevention-is-goal-of-alzheimers-drug-trial.html
- Wikipedia: Crenezumab
http://en.wikipedia.org/wiki/Crenezumab
- Yang T, Dang Y, Ostaszewski B, Mengel D et al
Target engagement in an alzheimer trial: Crenezumab lowers amyloid beta
oligomers in cerebrospinal fluid
Ann Neurol. 2019 Aug;86(2):215-224
PMID: 31168802 Free PMC article Clinical Trial.
- Ostrowitzki S, Bittner T, Sink KM et al
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early
Alzheimer DiseaseTwo Phase 3 Randomized Placebo-Controlled Trials.
JAMA Neurol. 2022;79(11):1113-1121.
PMID: 36121669 PMCID: PMC9486635 Free PMC article
https://jamanetwork.com/journals/jamaneurology/fullarticle/2796551